Last reviewed · How we verify
Vancomycin plus Rifampin
Vancomycin and rifampin work synergistically to inhibit bacterial cell wall and protein synthesis, providing broad-spectrum bactericidal activity against resistant gram-positive organisms.
Vancomycin and rifampin work synergistically to inhibit bacterial cell wall and protein synthesis, providing broad-spectrum bactericidal activity against resistant gram-positive organisms. Used for Serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA), Bacterial endocarditis, Osteomyelitis and other bone/joint infections.
At a glance
| Generic name | Vancomycin plus Rifampin |
|---|---|
| Sponsor | Michael E. DeBakey VA Medical Center |
| Drug class | Antibiotic combination |
| Target | Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, while rifampin inhibits bacterial RNA polymerase to suppress protein synthesis. This combination is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-positive bacteria, with demonstrated synergy in treating serious infections including endocarditis and osteomyelitis.
Approved indications
- Serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA)
- Bacterial endocarditis
- Osteomyelitis and other bone/joint infections
- Prosthetic valve infections
Common side effects
- Nephrotoxicity
- Ototoxicity
- Red man syndrome (vancomycin)
- Hepatotoxicity (rifampin)
- Drug interactions (rifampin)
- Thrombophlebitis at infusion site
Key clinical trials
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) (PHASE4)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection (PHASE2)
- Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (PHASE2)
- Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin (PHASE4)
- Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin plus Rifampin CI brief — competitive landscape report
- Vancomycin plus Rifampin updates RSS · CI watch RSS
- Michael E. DeBakey VA Medical Center portfolio CI